Antero Abrunhosa

Director of the Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra

Ferid Haddad

Directeur GIP Arronax, Professeur des université, Université de Nantes

ACCELERATE.EU: At-211 Targeted Alpha Therapy: From Bench to Bedside – An European Industry-Academia Partnership Initiative

ABSTRACT

ACCELERATE.EU, co-funded by the EU, brings together 17 leading European institutions and companies across 9 countries, blending academic expertise with industrial innovation to develop new alpha therapy solutions based on At-211 for 3 aggressive cancers. It is a five-year initiative. In this presentation, we will describe our consortium, the network of producer set up to support both preclinical and clinical works and detailed how we intend to develop and test new At-211 therapeutic agents for triple-negative breast cancer, pancreatic cancer, and glioblastoma.

Return to conference agenda